|
Feb 13
|
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer
|
|
Feb 13
|
Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update
|
|
Oct 10
|
Sonnet BioTherapeutics’ Strategic Deal to Develop DPN Treatment
|
|
Oct 9
|
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India
|
|
Oct 4
|
Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs
|
|
Jul 24
|
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
|
|
Jun 20
|
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
|
|
Jun 13
|
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
|
|
Mar 19
|
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
|
|
Dec 21
|
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
|
|
Oct 25
|
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
|